Adult-Onset Still Disease Treatment Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight | Cerecor, Roche, Swedish Orphan Biovitrum, Novartis, Swedish Orphan Biovitrum, AB2 Bio Ltd

DelveInsight's "Adult-onset Still's Disease Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of AOSD, historical and forecasted epidemiology, as well as the AOSD market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Unlock key insights into the Adult-onset Still Disease Market! Download DelveInsight's comprehensive report to explore market trends, pipeline analysis, and emerging therapies @ Adult-onset Still Disease Therapeutics Market Outlook- https://www.delveinsight.com/sample-request/adult-onset-still-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Adult-onset Still Disease Market Report
• In March 2025, Swedish Orphan Biovitrum announced a study to demonstrate efficacy and safety of anakinra in pediatric and adult Japanese patients with Still's disease (Systemic juvenile idiopathic arthritis [SJIA] and Adult-onset Still's disease [AOSD]). Core phase comprising 2 weeks double blind placebo-controlled treatment, 52 weeks open label treatment and 4 weeks safety follow up (only for patients not entering the extension phase).
• According to DelveInsight's epidemiology model, in the US, the total diagnosed prevalent cases of AOSD were approximately 2,325 in 2023. This number is anticipated to rise during the forecast period (2024-2034), driven by increased awareness and screening, along with advancements in genetic testing.
• Among the EU4 and the UK, Germany accounted for the highest number of diagnosed prevalent cases of AOSD, with approximately 691 cases in 2023, followed by France with approximately 560 cases, and the UK with nearly 550 cases.
• Among the gender-specific diagnosed prevalent cases of AOSD in the US in 2023, there were approximately 1,627 cases for females and around 697 cases for males.
• In 2023, Japan had the highest number of diagnosed prevalent cases of AOSD among the 7MM, totaling approximately 2,362 cases.2019
• In 2023, complications were categorized into Reactive Hemophagocytic Syndrome (RHS) and Macrophage Activation Syndrome (MAS). Notably, Macrophage Activation Syndrome (MAS) had a higher prevalence, with approximately 373 cases, compared to 307 cases of Reactive Hemophagocytic Syndrome (RHS) reported in Japan.
• The leading Adult-Onset Still Disease Companies such as Cerecor, Roche, Swedish Orphan Biovitrum, Novartis, Swedish Orphan Biovitrum, AB2 Bio Ltd., and others.
• Promising Adult-Onset Still Disease Pipeline Therapies such as GNR-086, Anakinra, Ilaris®, Canakinumab, Emapalumab, Seletracetam (UCB44212) and others.

Stay ahead in the competitive landscape of the Adult-Onset Still Disease Market. Access DelveInsight's in-depth market analysis and strategic insights today! Click here for more @ Adult-Onset Still Disease Treatment Market Size- https://www.delveinsight.com/sample-request/adult-onset-still-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Adult-Onset Still Disease Epidemiology Segmentation in the 7MM
• Total Adult-Onset Still Disease Prevalent Cases
• Total Adult-Onset Still Disease Diagnosed Prevalent Cases
• Adult-Onset Still Disease Gender-specific Diagnosed Prevalent Cases
• Adult-Onset Still Disease Complication associated Diagnosed Prevalent Cases

Download the report to understand which factors are driving Adult-Onset Still Disease epidemiology trends @ Adult-Onset Still Disease Prevalence- https://www.delveinsight.com/sample-request/adult-onset-still-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Adult-onset Still's Disease Marketed Drugs
• ILARIS (canakinumab): NOVARTIS
ILARIS (canakinumab), a human monoclonal anti-human IL-1ß antibody of the IgG1/? isotype, was approved by the FDA in June 2020, for the treatment of AOSD in patients aged 2 years and older, including both systemic juvenile idiopathic arthritis (SJIA) and AOSD. Canakinumab works by binding to IL-1ß and neutralizing its activity, thus blocking its interaction with IL-1 receptors, a crucial mechanism in controlling the inflammatory response in conditions like AOSD. The FDA granted ILARIS Priority Review designation, recognizing its potential to significantly improve the safety or effectiveness of treating a serious condition.

• KINERET (anakinra): Swedish Orphan Biovitrum
KINERET (anakinra) is indicated in Europe for the treatment of rheumatoid arthritis (RA) in adults who have had an inadequate response to methotrexate alone, and for treating cryopyrin-associated periodic syndromes (CAPS) in patients aged 8 months and older with a body weight of 10 kg or more. It is also approved for treating Still's disease, including SJIA and AOSD with moderate to high disease activity or continued disease activity after NSAIDs or glucocorticoids. KINERET can be administered as monotherapy or in combination with other anti-inflammatory drugs and DMARDs.

• ACTEMRA (tocilizumab): Genentech (ROCHE)
ACTEMRA (tocilizumab), a humanized anti-human IL-6 receptor monoclonal antibody, is approved for the treatment of AOSD in both the United States and Japan. The FDA granted approval in 2017, recognizing ACTEMRA's efficacy in targeting IL-6 receptors to mitigate the inflammatory response associated with AOSD. In May 2019, Chugai Pharmaceutical announced that it had secured regulatory approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for ACTEMRA Intravenous Infusion (80 mg, 200 mg, and 400 mg) for adult Still's disease, particularly in cases unresponsive to existing therapies, along with an additional dosing regimen. ACTEMRA'S approval underscores its therapeutic significance in addressing unmet needs in this challenging condition.

Emerging Adult-onset Still's Disease Drugs
• Tadekinig Alfa: AB2 Bio
Tadekinig alfa is a recombinant Interleukin-18 Binding Protein (r-hIL-18BP) designed to target IL-18, a key inflammatory cytokine involved in various inflammatory diseases. In healthy individuals, naturally occurring IL-18BP maintains low levels of free IL-18, but in patients with certain inflammatory conditions, this balance is disrupted, leading to elevated free IL-18 levels and pathological inflammation. By administering AB2 Bio's exogenous recombinant human IL-18BP, the IL-18/IL-18BP balance is restored, effectively removing excess free IL-18 and reducing inflammation.

To learn more about Adult-Onset Still Disease treatment guidelines, visit @ Adult-Onset Still Disease Market Drivers and Barriers- https://www.delveinsight.com/sample-request/adult-onset-still-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Adult-Onset Still's Disease Drug Class Insights
The treatment of AOSD involves several classes of medications tailored to address varying degrees of inflammation and disease severity. Nonsteroidal anti-inflammatory drugs (NSAIDs) serve as first-line therapies to alleviate pain and reduce inflammation, though their efficacy may be limited in more severe cases. When NSAIDs prove inadequate, corticosteroids are commonly prescribed to provide rapid anti-inflammatory effects and immune suppression. For patients who do not respond to these conventional therapies, biologic disease-modifying antirheumatic drugs (bDMARDs) are increasingly utilized, targeting specific pathways in the inflammatory process to improve clinical outcomes.

Adult-onset Still's Disease Market Outlook
AOSD is an autoinflammatory syndrome driven by the innate immune system, characterized by symptoms such as fever, rash, arthritis, pharyngitis, and hepatic and splenic involvement. Due to the rarity of AOSD and a lack of large-scale studies, diagnosis is often challenging, leading to an empirical treatment approach based on small retrospective case series.

Explore the dynamics of the Adult-Onset Still Disease Market with DelveInsight. From market size to emerging drugs-find it all in our latest report. Read now! @ Adult-Onset Still Disease Ongoing Clinical Trials Analysis- https://www.delveinsight.com/sample-request/adult-onset-still-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Adult-Onset Still Disease Market Report
• Coverage- 7MM
• Study Period- 2020-2034
• Adult-Onset Still Disease Companies- Cerecor, Roche, Swedish Orphan Biovitrum, Novartis, Swedish Orphan Biovitrum, AB2 Bio Ltd., and others.
• Adult-Onset Still Disease Pipeline Therapies- GNR-086, Anakinra, Ilaris®, Canakinumab, Emapalumab, Seletracetam (UCB44212) and others.
• Adult-Onset Still Disease Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Adult-Onset Still Disease Unmet Needs, KOL's views, Analyst's views, Adult-Onset Still Disease Market Access and Reimbursement

To know more about Adult-Onset Still Disease Companies working in the treatment market, visit @ Adult-Onset Still Disease Clinical Trials and Therapeutic Assessment- https://www.delveinsight.com/sample-request/adult-onset-still-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1 Key Insights
2 Executive Summary of AOSD
3 Adult-onset Still's Disease Market Overview at a Glance
4 Adult-Onset Still Disease Overview and Background
5 Adult-Onset Still Disease Treatment
6 Organizations contributing toward AOSD
7 Case Study
8 Adult-Onset Still Disease Epidemiology and Patient Population
9 7MM Adult-Onset Still Disease Epidemiology
10 Marketed Adult-Onset Still's Disease Drugs
11 Adult-Onset Still Disease Emerging Drugs
12 Adult-Onset Still Disease Market Analysis
14 Adult-Onset Still Disease SWOT Analysis
15 Adult-Onset Still Disease Unmet Needs
16 Adult-Onset Still Disease Market Access and Reimbursement
17 Appendix
18 DelveInsight Capabilities
19 Disclaimer
20 About DelveInsight

List of Top Selling Market Research Reports in 2025

ADHD Market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Periodontal disease market- https://www.delveinsight.com/report-store/periodontal-disease-market
Surgical energy instruments Market- https://www.delveinsight.com/report-store/surgical-energy-instruments-electrosurgical-devices-market
Surgical robotic system market- https://www.delveinsight.com/report-store/surgical-robotic-system-market
NK Cell Therapy market- https://www.delveinsight.com/report-store/nk-cell-therapy-market
Vital sign monitors devices market- https://www.delveinsight.com/report-store/vital-sign-monitors-external-remote-patient-monitoring-devices-market
Thrombectomy devices market- https://www.delveinsight.com/report-store/thrombectomy-devices-market
Urea cycle disorders market- https://www.delveinsight.com/report-store/urea-cycle-disorders-market
Diabetic wound market- https://www.delveinsight.com/report-store/diabetic-wounds-market
Indwelling catheters market- https://www.delveinsight.com/report-store/urinary-catheters-market
Positive airway pressure device market- https://www.delveinsight.com/report-store/positive-airway-pressure-device-market
Stem cell market- https://www.delveinsight.com/report-store/stem-cell-market
Thyroid cancer market- https://www.delveinsight.com/report-store/thyroid-cancer-market
LY3454738 drug insight- https://www.delveinsight.com/report-store/moderate-to-severe-atopic-dermatitis-pipeline-insight
Antibody drug conjugate market- https://www.delveinsight.com/report-store/antibody-drug-conjugate-adc-market
Bone growth stimulator market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
Medical marijuana market- https://www.delveinsight.com/report-store/medical-marijuana-market-insight
Surgical mask & respirator market- https://www.delveinsight.com/report-store/surgical-mask-respirator-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: +91-9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.